SRR1313143
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.350
- MYC_TARGETS_V1+0.210
- DNA_REPAIR+0.200
- SPERMATOGENESIS+0.200
- MITOTIC_SPINDLE+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.030
- WNT_BETA_CATENIN_SIGNALING-0.030
- HEME_METABOLISM-0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- COAGULATION-0.490
- ESTROGEN_RESPONSE_EARLY-0.460
- ANGIOGENESIS-0.440
- APICAL_JUNCTION-0.440
- ESTROGEN_RESPONSE_LATE-0.430
- IL2_STAT5_SIGNALING-0.430
- COMPLEMENT-0.410
- INFLAMMATORY_RESPONSE-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1BWP5MCT | medulloblastoma | — | 0.950 |
| 2 | BS_9V633J1X | medulloblastoma | — | 0.947 |
| 3 | SRR1313141 | — | E | 0.946 |
| 4 | SAMN03290905 | — | — | 0.941 |
| 5 | TCGA-18-4083-01A-01R-A96U-41 | — | cohortSQ2 | 0.936 |
| 6 | BS_GE2RVZE6 | medulloblastoma | — | 0.935 |
| 7 | BS_3NWQXPQV | medulloblastoma | — | 0.934 |
| 8 | BS_V9HVBBDW | medulloblastoma | — | 0.931 |
| 9 | BS_D0RDN4K5 | Embryonal tumors | — | 0.930 |
| 10 | BS_9PB3XH5D | medulloblastoma | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |